RIBOPHARMA AG
Development and marketing of SIRPLEX, a pharmaceutical substance based on double-stranded RNA.
RIBOPHARMA AG
Industry:
Biotechnology Marketing Pharmaceutical
Founded:
2000-01-01
Website Url:
http://www.ribopharma.de
Status:
Closed
Technology used in webpage:
Domain Not Resolving
Similar Organizations
i2 Pharmaceuticals
i2 Pharmaceuticals, a biopharmaceutical company.
Palo Santo Fund
Palo Santo Fund is an investment fund that invests in psychedelic and healthcare industry.
Wellington Pharmaceuticals
Wellington Pharmaceuticals is a pharmaceutical manufacturing company located in .
More informations about "Ribopharma AG"
Ribopharma AG - Crunchbase Company Profile
Ribopharma AG merged with Alnylam Pharmaceuticals on Sep 7, 2003. Where is Ribopharma AG's headquarters? Ribopharma AG is located in Kulmbach, …See details»
Ribopharma AG - life-sciences-europe.com
BIO (US) (Biotechnology Innovation Organization, formerly Biotechnology Industry Organization) ... //www.ribopharma.de. Start: 2000-01-01 established End: 2003-07-07 merged Group: LGC …See details»
Ribopharma - Products, Competitors, Financials, Employees, …
Ribopharma was founded in 2000. Where is Ribopharma's headquarters? Ribopharma's headquarters is located at Fritz-Hornschuh-Strasse 9, Kulmbach. What is Ribopharma's latest …See details»
Reflections on Alnylam - Nature Biotechnology
May 9, 2022 · Merging with Ribopharma would extend our patent leadership, enhance our research capabilities and fulfill our Max Planck obligations in Europe in one fell swoop.See details»
Ribopharma AG - Company Profile & Staff Directory - ContactOut
Discover Ribopharma AG company details, including staff directory, contact information, and industry insights. Explore alternatives, competitors, and frequently asked questions to get …See details»
RNAi Companies Ribopharma, Alnylam Merge, Raise $24.6M
Jul 8, 2003 · A hot young section of the industry is seeing some consolidation already, as Alnylam Pharmaceuticals Inc. merged with its counterpart in Germany, Ribopharma AG, and …See details»
Alnylam’s 20-Year Journey of Discovery
Twenty years ago, a group of scientists intent on developing a new class of medicine using RNAi technology came together and formed Alnylam Pharmaceuticals, a name symbolizing their …See details»
Alnylam - Abingworth LLP
Alnylam is developing novel RNA interference- (RNAi-) based therapeutics that use double-stranded RNA to prevent the expression of specific genes. The company has several …See details»
Alnylam Pharmaceuticals and Ribopharma fusionieren zum …
Die beiden führenden Unternehmen auf dem Gebiet der Entwicklung von Therapeutika auf Basis der RNA-Interferenz (RNAi), Alnylam Pharmaceuticals, Inc. und Ribopharma AG, gaben heute …See details»
Ribopharma Management Team - CB Insights
Ribopharma has 3 executives. Ribopharma's current Chief Executive Officer is Roland Kreutzer. You're one click away from the most comprehensive, unmatched analyst expertise in tech, in …See details»
Ribopharma in all share merger with Alnylam
Jul 13, 2003 · Kulmbach, Germany-headquartered Ribopharma AG has merged with the USA's Alnylam Pharmaceuticals in a stock-for-stock deal that creates a leading biotechnology …See details»
Alnylam Pharmaceuticals acquires Ribopharma AG - 2003-09-07 ...
Ribopharma AG Development and marketing of SIRPLEX, a pharmaceutical substance based on double-stranded RNA. Acquiring Organization: Alnylam Pharmaceuticals Alnylam …See details»
Alnylam and Ribopharma Announce Merger - Labmedica.com
Jul 18, 2003 · A merger that creates an international company with a leading position in RNA interference (RNAi)-based therapeutics has been announced by Alnylam Pharmaceuticals, …See details»
Ribopharma AG - BioCentury Company Profiles - BCIQ
Apr 15, 2013 · Explore BCIQ profiles by entering a company name.See details»
Reflections on Alnylam - Nature
In this personal reflection, and as Alnylam embarks on its 20th year as a company leading the RNA interference (RNAi) revolution, I want to highlight the highs and lows of building a …See details»
Alnylam Pharmaceuticals - Wikipedia
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for …See details»
Corporate Activity — Mergers and Acquisitions
Sep 21, 2012 · Perhaps reflecting the growing interest in RNA interference-based therapeutics, US company Alnylam Pharmaceuticals and Ribopharma of Germany have merged (p42). The …See details»
Ribopharma Stock Price, Funding, Valuation, Revenue ... - CB Insights
Jul 30, 2003 · See Ribopharma funding rounds, investors, investments, exits and more. Evaluate their financials based on Ribopharma's post-money valuation and revenue.See details»
RNAi Companies Ribopharma, Alnylam Merge, Raise $24.6M
Jul 8, 2003 · A hot young section of the industry is seeing some consolidation already, as Alnylam Pharmaceuticals Inc. merged with its counterpart in Germany, Ribopharma AG, and …See details»
RNAi Firms Unite Rather than Fight - insights.citeline.com
In the hot new field of RNAi research, both Alnylam Pharmaceuticals and Ribopharma felt they controlled vital intellectual property. To end uncertainty offputting to potential partners and …See details»